{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T17:02:34Z","timestamp":1790960554479,"version":"4.1.0"},"reference-count":30,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2017,8,1]],"date-time":"2017-08-01T00:00:00Z","timestamp":1501545600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,8,1]],"date-time":"2017-08-01T00:00:00Z","timestamp":1501545600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2017,2,7]],"date-time":"2017-02-07T00:00:00Z","timestamp":1486425600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaad.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Academy of Dermatology"],"published-print":{"date-parts":[[2017,8]]},"DOI":"10.1016\/j.jaad.2017.01.052","type":"journal-article","created":{"date-parts":[[2017,4,14]],"date-time":"2017-04-14T11:27:55Z","timestamp":1492169275000},"page":"310-317.e1","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":161,"title":["Long-term safety and tolerability of apremilast in patients with psoriasis: Pooled safety analysis for \u2265156\u00a0weeks from 2 phase 3, randomized, controlled trials (ESTEEM 1 and 2)"],"prefix":"10.1016","volume":"77","author":[{"given":"Jeffrey","family":"Crowley","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diamant","family":"Tha\u00e7i","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pascal","family":"Joly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ketty","family":"Peris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kim A.","family":"Papp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joana","family":"Goncalves","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert M.","family":"Day","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rongdean","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kamal","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"Ferr\u00e1ndiz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer C.","family":"Cather","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.jaad.2017.01.052_bib1","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.amepre.2014.02.012","article-title":"Prevalence of psoriasis among adults in the U.S.: 2003-2006 and 2009-2010 National Health and Nutrition Examination surveys","volume":"47","author":"Helmick","year":"2014","journal-title":"Am J Prev Med"},{"issue":"3","key":"10.1016\/j.jaad.2017.01.052_bib2","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1016\/j.jaad.2013.11.013","article-title":"Psoriasis prevalence among adults in the United States","volume":"70","author":"Rachakonda","year":"2014","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"10.1016\/j.jaad.2017.01.052_bib3","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1038\/jid.2012.339","article-title":"Global epidemiology of psoriasis: a systematic review of incidence and prevalence","volume":"133","author":"Parisi","year":"2013","journal-title":"J Invest Dermatol"},{"issue":"11","key":"10.1016\/j.jaad.2017.01.052_bib4","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1001\/archdermatol.2011.309","article-title":"Patient preferences for psoriasis treatments: process characteristics can outweigh outcome attributes","volume":"147","author":"Schaarschmidt","year":"2011","journal-title":"Arch Dermatol"},{"issue":"4","key":"10.1016\/j.jaad.2017.01.052_bib5","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1177\/247553031420a00404","article-title":"Patient perspectives on psoriasis management: U.S. results of the population-based Multinational Assessment of Psoriasis and Psoriatic Arthritis survey","volume":"20","author":"Lebwohl","year":"2014","journal-title":"Psoriasis Forum"},{"issue":"8","key":"10.1016\/j.jaad.2017.01.052_bib6","first-page":"20","article-title":"A practical approach to monitoring patients on biological agents for the treatment of psoriasis","volume":"3","author":"Emer","year":"2010","journal-title":"J Clin Aesthet Dermatol"},{"issue":"1","key":"10.1016\/j.jaad.2017.01.052_bib7","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1001\/jamadermatol.2015.3605","article-title":"Psoriasis and the risk of depression in the US population: National Health and Nutrition Examination survey 2009-2012","volume":"152","author":"Cohen","year":"2016","journal-title":"JAMA Dermatol"},{"issue":"9","key":"10.1016\/j.jaad.2017.01.052_bib8","doi-asserted-by":"crossref","first-page":"2016","DOI":"10.1016\/j.cellsig.2014.05.014","article-title":"Apremilast is a selective PDE4 inhibitor with regulatory effects on innate immunity","volume":"26","author":"Schafer","year":"2014","journal-title":"Cell Signal"},{"issue":"1","key":"10.1016\/j.jaad.2017.01.052_bib9","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.jaad.2015.03.049","article-title":"Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM 1])","volume":"73","author":"Papp","year":"2015","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"10.1016\/j.jaad.2017.01.052_bib10","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1111\/bjd.14164","article-title":"Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate to severe plaque psoriasis over 52 weeks: a phase III, randomized, controlled trial (ESTEEM 2)","volume":"173","author":"Paul","year":"2015","journal-title":"Br J Dermatol"},{"issue":"1","key":"10.1016\/j.jaad.2017.01.052_bib11","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.jaad.2015.09.001","article-title":"Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with difficult-to-treat nail and scalp psoriasis: results of 2 phase III randomized, controlled trials (ESTEEM 1 and ESTEEM 2)","volume":"74","author":"Rich","year":"2016","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"6","key":"10.1016\/j.jaad.2017.01.052_bib12","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1136\/annrheumdis-2015-207963","article-title":"Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis and current skin involvement: a phase III, randomised, controlled trial (PALACE 3)","volume":"75","author":"Edwards","year":"2016","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"10.1016\/j.jaad.2017.01.052_bib13","doi-asserted-by":"crossref","first-page":"479","DOI":"10.3899\/jrheum.140647","article-title":"Longterm (52-week) results of a phase III randomized, controlled trial of apremilast in patients with psoriatic arthritis","volume":"42","author":"Kavanaugh","year":"2015","journal-title":"J Rheumatol"},{"key":"10.1016\/j.jaad.2017.01.052_bib14","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.jaad.2016.02.1164","volume":"75","author":"Bissonnette","year":"2016","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"10.1016\/j.jaad.2017.01.052_bib15","doi-asserted-by":"crossref","first-page":"514","DOI":"10.2340\/00015555-2360","article-title":"Effects of apremilast on pruritus and skin discomfort\/pain correlate with improvements in quality of life in patients with moderate to severe\u00a0plaque psoriasis","volume":"96","author":"Sobell","year":"2016","journal-title":"Acta Derm Venereol"},{"issue":"5","key":"10.1016\/j.jaad.2017.01.052_bib16","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1111\/j.1365-2133.2012.10830.x","article-title":"A systematic review of worldwide incidence of nonmelanoma skin cancer","volume":"166","author":"Lomas","year":"2012","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2017.01.052_bib17","series-title":"Therapeutic targets: modulation, inhibition, and activation","first-page":"1","article-title":"cAMP-specific phosphodiesterases: modulation, inhibition, and activation","author":"Cameron","year":"2012"},{"issue":"3","key":"10.1016\/j.jaad.2017.01.052_bib18","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1165\/rcmb.2013-0228OC","article-title":"Cystic fibrosis transmembrane conductance regulator activation by roflumilast contributes to therapeutic benefit in chronic bronchitis","volume":"50","author":"Lambert","year":"2014","journal-title":"Am J Respir Cell Mol Biol"},{"issue":"5","key":"10.1016\/j.jaad.2017.01.052_bib19","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1016\/S0016-5085(76)80353-8","article-title":"Effect of caffeine on the human small intestine","volume":"71","author":"Wald","year":"1976","journal-title":"Gastroenterology"},{"issue":"1","key":"10.1016\/j.jaad.2017.01.052_bib20","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.jchemneu.2010.03.004","article-title":"The human area postrema and other nuclei related to the emetic reflex express cAMP phosphodiesterases 4B and 4D","volume":"40","author":"Mori","year":"2010","journal-title":"J Chem Neuroanat"},{"issue":"2","key":"10.1016\/j.jaad.2017.01.052_bib21","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/S0028-3908(98)00190-7","article-title":"Emesis\u00a0induced by inhibitors of type IV cyclic nucleotide phosphodiesterase (PDE IV) in the ferret","volume":"38","author":"Robichaud","year":"1999","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.jaad.2017.01.052_bib22","unstructured":"Abraham BP, Shah K, Levi E, Sellin JH. Apremilast for the treatment of psoriasis and psoriatic arthritis: management of gastrointestinal adverse effects [poster]. Presented at: Annual Maui Derm for Dermatologists; January 25-29, 2016; Maui, HI."},{"key":"10.1016\/j.jaad.2017.01.052_bib23","series-title":"Otezla [package insert]","year":"2015"},{"issue":"5","key":"10.1016\/j.jaad.2017.01.052_bib24","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1007\/s40259-015-0144-3","article-title":"Selective phosphodiesterase inhibitors for psoriasis: focus on apremilast","volume":"29","author":"Gooderham","year":"2015","journal-title":"Biodrugs"},{"issue":"6","key":"10.1016\/j.jaad.2017.01.052_bib25","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1038\/jid.2013.508","article-title":"The prevalence and odds of depressive symptoms and clinical depression in psoriasis patients: a systematic review and meta-analysis","volume":"134","author":"Dowlatshahi","year":"2014","journal-title":"J Invest Dermatol"},{"issue":"12","key":"10.1016\/j.jaad.2017.01.052_bib26","first-page":"1441","article-title":"Safety observations in 12,095 patients with psoriasis enrolled in an international registry (PSOLAR): experience with infliximab and other systemic and biologic therapies","volume":"13","author":"Gottlieb","year":"2014","journal-title":"J Drugs Dermatol"},{"issue":"9","key":"10.1016\/j.jaad.2017.01.052_bib27","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1001\/jamadermatol.2015.0718","article-title":"Risk of serious infection with biologic and systemic treatment of psoriasis: results from the Psoriasis Longitudinal Assessment and Registry (PSOLAR)","volume":"151","author":"Kalb","year":"2015","journal-title":"JAMA Dermatol"},{"issue":"5","key":"10.1016\/j.jaad.2017.01.052_bib28","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1111\/bjd.14068","article-title":"Cohort study of malignancies and hospitalized infectious events in treated and untreated patients with\u00a0psoriasis and a general population in the United States","volume":"173","author":"Kimball","year":"2015","journal-title":"Br J Dermatol"},{"issue":"6","key":"10.1016\/j.jaad.2017.01.052_bib29","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1111\/ajt.13181","article-title":"Evaluation of the effect of tofacitinib exposure on outcomes in kidney transplant patients","volume":"15","author":"Vincenti","year":"2015","journal-title":"Am J Transplant"},{"issue":"2","key":"10.1016\/j.jaad.2017.01.052_bib30","doi-asserted-by":"crossref","first-page":"332","DOI":"10.2215\/CJN.08570814","article-title":"Immunosuppressive medications","volume":"11","author":"Wiseman","year":"2016","journal-title":"Clin J Am Soc Nephrol"}],"container-title":["Journal of the American Academy of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962217301469?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962217301469?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T22:42:47Z","timestamp":1759272167000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0190962217301469"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,8]]},"references-count":30,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2017,8]]}},"alternative-id":["S0190962217301469"],"URL":"https:\/\/doi.org\/10.1016\/j.jaad.2017.01.052","relation":{},"ISSN":["0190-9622"],"issn-type":[{"value":"0190-9622","type":"print"}],"subject":[],"published":{"date-parts":[[2017,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Long-term safety and tolerability of apremilast in patients with psoriasis: Pooled safety analysis for \u2265156\u00a0weeks from 2 phase 3, randomized, controlled trials (ESTEEM 1 and 2)","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Academy of Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaad.2017.01.052","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 by the American Academy of Dermatology, Inc.","name":"copyright","label":"Copyright"}]}}